Safety, Tolerability, and PK/PD of JUV-161 in Healthy Adult Volunteers

Phase 1, randomised, double-blind trial of JUV-161 in myotonic dystrophy type 1 (DM1) (2 arms), sponsored by Juvena Therapeutics. Primary endpoints: Incidence of treatment-emergent adverse events at Day 60, Number of participants with treatment-emergent potentially clinically-significant safety abnormalities in safety laboratory parameters at Day 60 and 3 more. Started May 2025; status: active, not recruiting.